Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

[1]  J. Blay,et al.  Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma. , 2012 .

[3]  J. Blay,et al.  A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. , 2012 .

[4]  J. Blay,et al.  Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib , 2012, Annals of Surgical Oncology.

[5]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[6]  C. Tournigand,et al.  Progression-free survival ratio as end point for phase II trials in advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Emanuela M. Ghia,et al.  Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling , 2011, Genes, chromosomes & cancer.

[8]  B. Rubin,et al.  Automated Brightfield Dual-Color In Situ Hybridization for Detection of Mouse Double Minute 2 Gene Amplification in Sarcomas , 2011, Applied immunohistochemistry & molecular morphology (Print).

[9]  J. Manfredi.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[10]  J. Blay,et al.  Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region , 2010, BMC Cancer.

[11]  J. Coindre,et al.  Well-differentiated and dedifferentiated liposarcomas , 2010, Virchows Archiv.

[12]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Robin L. Jones,et al.  Differential sensitivity of liposarcoma subtypes to chemotherapy. , 2005, European journal of cancer.

[15]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[16]  Hui Wang,et al.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. , 2005, Current cancer drug targets.

[17]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[18]  L. Vassilev,et al.  Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. , 2003, Molecular cancer therapeutics.

[19]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[20]  F. Collin,et al.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas , 2001, Cancer.

[21]  R J Carroll,et al.  Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. , 2000, Controlled clinical trials.

[22]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[23]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[24]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[25]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[26]  Thierry Soussi,et al.  TP53 mutations in human cancer: database reassessment and prospects for the next decade. , 2011, Advances in cancer research.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.

[29]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[30]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[31]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.